NCT04503850

Impact of Mirabegron on Erectile Function in BPH Patients

Impact of Beta 3 Agonist Mirabegron on Erectile Function on Patients With Benign Prostate Hyperplasia

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Kasr El Aini Hospital · Academic / Other
• Sex: Male
• Age: 50 Years
• Healthy volunteers: —

Summary

Evaluation of impact of Mirabegron on erectile function for patients treated for BPH

Detailed description

50 patients (Group A) will receive Mirabegron \& alpha blocker 50 patients (Group B) will receive alpha blocker only Evaluation using IIEF 5 scoring system

Conditions

• Males With Benign Prostatic Hyperplasia Symptoms

Interventions

Type	Name	Description
DRUG	Mirabegron 50 MG	Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
DRUG	Alpha Blockers	Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-05-01
• Completion: 2021-10-01
• First posted: 2020-08-07
• Last updated: 2020-08-10

Regulatory

• FDA-regulated drug study